AstraZeneca’s shareholders rebel over pay
Biotech stocks

AstraZeneca’s shareholders rebel over pay

Shareholders in AstraZeneca have rebelled over proposals to raise bonus levels for its bosses.
14 May 2021
Merck: the good value biotech stock that has cornered the cancer market
Share tips

Merck: the good value biotech stock that has cornered the cancer market

Merck, the biopharma giant, dominates the biggest disease sector and looks reasonably valued, says Dr Mike Tubbs.
27 Apr 2021
Activist investor Elliott takes takes a stake in Glaxo
Biotech stocks

Activist investor Elliott takes takes a stake in Glaxo

Elliott, s US hedge fund, took an undisclosed multibillion-pound stake in GSK last week, driving the share price up by 4.6%.
22 Apr 2021
Get decades of growth at a discount with this healthcare investment trust
Investment trusts

Get decades of growth at a discount with this healthcare investment trust

Healthcare is set for strong long-term expansion but looks cheap. That makes this investment trust worth buying, says Max King.
19 Apr 2021
Moderna’s Stéphane Bancel: the maths nerd who struck vaccine gold
People

Moderna’s Stéphane Bancel: the maths nerd who struck vaccine gold

A decade ago, Stéphane Bancel took a gamble and joined a fledgling start-up working on an unproven new technology. The gamble paid off with the rise o…
17 Apr 2021
How the vaccine wars will harm us all
Global Economy

How the vaccine wars will harm us all

Grabbing and hoarding vaccine supplies, or even manufacturing one’s own, might seem to make sense for a state in an emergency. But the damage done to …
27 Mar 2021
AstraZeneca’s Pascal Soriot: in the crossfire of the vaccine wars
People

AstraZeneca’s Pascal Soriot: in the crossfire of the vaccine wars

AstraZeneca’s boss Pascal Soriot was winning plaudits for his stewardship when the Covid-19 pandemic struck. Since then, he’s been having a hard time …
27 Mar 2021
Scientific-instrument companies are a global success – here's how to play them
Share tips

Scientific-instrument companies are a global success – here's how to play them

Companies delivering scientific instruments – products to measure and analyse our world – are crucial to sectors ranging from telecommunications to ph…
26 Mar 2021
Three winners of the long-term biotech boom
Share tips

Three winners of the long-term biotech boom

Professional investor Marek Poszepcynski of the International Biotechnology Trust picks three biotech stocks with good pipelines, strong management te…
22 Mar 2021
The unscientific criticism of AstraZeneca could do lasting damage
Biotech stocks

The unscientific criticism of AstraZeneca could do lasting damage

Several European countries have suspended their use of AstraZeneca's Covid vaccine – for no good scientific reason. Matthew Partridge reports.
18 Mar 2021
Johnson & Johnson vaccine approval is another shot in the arm for the world
Biotech stocks

Johnson & Johnson vaccine approval is another shot in the arm for the world

Johnson & Johnson’s vaccine has been approved in the US, a sign that the world is making solid progress against Covid-19. Matthew Partridge reports
4 Mar 2021
How to invest in the latest developments in hearing technology
Biotech stocks

How to invest in the latest developments in hearing technology

Traditionally dismissed as a relative backwater, this branch of medicine is about to move into the limelight thanks to ageing populations and major br…
19 Feb 2021
Vanquishing the virus: the race to make vaccines for Covid-19
Biotech stocks

Vanquishing the virus: the race to make vaccines for Covid-19

The extraordinarily rapid development of effective treatments against the coronavirus is a triumph of biotechnology, says Dr Mike Tubbs. He reviews th…
12 Feb 2021
Vexing vaccine delays hit drug firms
Biotech stocks

Vexing vaccine delays hit drug firms

AstraZeneca and Pfizer are being attacked by the EU over what it claims are delays in delivering the Covid vaccine.
28 Jan 2021
AstraZeneca turns the tables as it acquires US pharmaceutical firm Alexion
Biotech stocks

AstraZeneca turns the tables as it acquires US pharmaceutical firm Alexion

AstraZeneca, the British pharma giant, was almost swallowed up by Pfizer a few years ago. Now it has struck a megadeal of its own. Matthew Partridge r…
17 Dec 2020
The lessons of “Operation Warp Speed” – the race to produce a vaccine
Biotech stocks

The lessons of “Operation Warp Speed” – the race to produce a vaccine

Governments and companies can learn from the extraordinary global effort to create a vaccine to defeat Covid-19, says Matthew Lynn.
13 Dec 2020
The MoneyWeek Podcast: Barry Norris on why he's shorting vaccine-makers
Biotech stocks

The MoneyWeek Podcast: Barry Norris on why he's shorting vaccine-makers

The news of Covid vaccines has delighted many. But not Argonaut Capital's Barry Norris. He tells Merryn why vaccines aren't the panacea people think t…
3 Dec 2020
Big Pharma deserves its reward for coming up with Covid-19 vaccines
Biotech stocks

Big Pharma deserves its reward for coming up with Covid-19 vaccines

Calls to restrain drug companies' profits from making Covid-19 vaccines are misplaced and would do more harm than good, says Matthew Lynn
29 Nov 2020
More good news as AstraZeneca finds a third Covid vaccine
Biotech stocks

More good news as AstraZeneca finds a third Covid vaccine

Another week, another Covid-19 vaccine. This one from AstraZeneca and Oxford University is homegrown and ready to roll out fast. Matthew Partridge rep…
26 Nov 2020
Ugur Sahin and Özlem Türeci : the boffins behind the Covid-19 vaccine
People

Ugur Sahin and Özlem Türeci : the boffins behind the Covid-19 vaccine

Ugur Sahin and Özlem Türeci are an unassuming Turkish-German couple who had already made their fortune as biotech entrepreneurs when a strange new vi…
21 Nov 2020
Moderna’s “stunning” second vaccine
Biotech stocks

Moderna’s “stunning” second vaccine

America’s Moderna has come up with a vaccine even more promising than last week’s offering from Pfizer and BioNTech. Matthew Partridge reports
19 Nov 2020
The market reaction to the vaccine shows the value of contrarian thinking
Investment strategy

The market reaction to the vaccine shows the value of contrarian thinking

As the vaccine news has shown, you don't have to think too far outside of the box to get ahead of the herd, says John Stepek.
17 Nov 2020
Is the BioNTech/Pfizer vaccine the big Covid-19 breakthrough?
Biotech stocks

Is the BioNTech/Pfizer vaccine the big Covid-19 breakthrough?

A vaccine that appears so far to be safe and effective is making its way through the final trials before commercialisation. There are reasons to be ch…
12 Nov 2020
Novo Nordisk: Denmark’s dominant drug maker
Share tips

Novo Nordisk: Denmark’s dominant drug maker

Novo Nordisk leads the global market in diabetes treatments and looks a solid long-term buy, says Dr Mike Tubbs.
4 Nov 2020